<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01990911</url>
  </required_header>
  <id_info>
    <org_study_id>RDPAF1</org_study_id>
    <nct_id>NCT01990911</nct_id>
  </id_info>
  <brief_title>Renal Sympathetic Denervation Prevents Atrial Fibrillation in Patients With Hypertensive Heart Disease: a Pilot Study</brief_title>
  <acronym>RDPAF</acronym>
  <official_title>Renal Sympathetic Denervation Restores Autonomic Imbalance and Prevents Atrial Fibrillation in Patients With Hypertensive Heart Disease: a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pace Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Saarland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pace Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The autonomic nervous system plays an important role in the precipitation of AF in&#xD;
      structurally-abnormal hearts. Restoration of autonomic imbalance may therefore prevent&#xD;
      new-onset AF.&#xD;
&#xD;
      Renal artery denervation (RDN) is a novel percutaneous procedure that uses radio-frequency&#xD;
      energy to destroy the sympathetic renal nerves. Symplicity 1 and -2 studies have shown that&#xD;
      RDN effectively reduces blood pressure in up to 80% of treated patients. LVH regression and&#xD;
      improvement of diastolic dysfunction follow as a consequence of afterload reduction and&#xD;
      renin-angiotensin-aldosterone system modulation. RDN may thus also reduce intra-atrial&#xD;
      pressure resulting in less stretch of the pulmonary venous ostia where most ectopic AF-foci&#xD;
      originate.&#xD;
&#xD;
      Hypothesis: RDN restores autonomic imbalance in HTHD and lowers intra-atrial pressure by&#xD;
      reducing afterload. These synergistic mechanisms may prevent new-onset AF.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      One hundred consenting patients meeting all inclusion criteria will undergo an exercise&#xD;
      stress test, 2D and M-Mode echocardiograms and 24-hour ambulatory blood pressure holter&#xD;
      monitoring prior to being randomised to receive either renal denervation (RDN) with a&#xD;
      Symplicity renal denervation catheter plus medical therapy or medical therapy alone. Coronary&#xD;
      angiography with/without coronary revascularisation will be performed as per the treating&#xD;
      cardiologist's clinical judgement and a Reveal® holter will be implanted in all patients at&#xD;
      the end of the procedure.&#xD;
&#xD;
      Time zero will be defined as starting at three months after the procedure. Follow up visits&#xD;
      will be scheduled to scan the holter for the primary end point, i.e. high atrial rates&#xD;
      (AF-surrogate defined as: &quot;episodes of atrial rate &gt;190 beats per minute for more than 6&#xD;
      minutes&quot;) or new-onset AF. Patients will be followed six monthly for three years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 2013</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Atrial fibrillation</measure>
    <time_frame>3 years</time_frame>
    <description>Subclinical atrial tachyarrhythmias (episodes of atrial rate &gt;190 beats per minute for more than 6 minutes) or atrial fibrillation recorded by implantable loop recorder (Reveal® holter).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Restoration of autonomic imbalance</measure>
    <time_frame>3 years</time_frame>
    <description>Restoration of autonomic imbalance: lowering resting heart rate, prolonging the PR-interval and improving heart rate recovery after exercise.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hypertension</condition>
  <condition>Hypertensive Heart Disease</condition>
  <condition>Atrial Fibrillation</condition>
  <condition>Autonomic Imbalance</condition>
  <arm_group>
    <arm_group_label>Renal denervation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Renal denervation: both renal arteries are denervated by applying radio-frequency energy at application points moving in a helical fashion starting in the distal renal artery and moving to the proximal junction with the abdominal aorta.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medical therapy</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>This group will not receive renal sympathetic denervation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Renal denervation</intervention_name>
    <description>In patients randomized to intervention both renal arteries will be treated with radio-frequency energy as per standard Symplicity protocol.In patients randomized to medical-treatment group only, sham renal denervation will be performed by only injecting contrast agent into both renal arteries.</description>
    <arm_group_label>Renal denervation</arm_group_label>
    <other_name>Symplicity catheter renal denervation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Medical therapy</intervention_name>
    <description>Subjects will continue on their standard medical therapy as prescribed by their treating physician</description>
    <arm_group_label>Medical therapy</arm_group_label>
    <arm_group_label>Renal denervation</arm_group_label>
    <other_name>Three or more blood pressure tablets, including a diuretic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must have an indication for coronary angiography e.g.&#xD;
&#xD;
          -  Acute coronary syndrome&#xD;
&#xD;
          -  Positive stress ECG: - Defined as ≥1mm ST segment shift (depression or elevation) in&#xD;
             ≥2 contiguous leads with/without chest discomfort)&#xD;
&#xD;
          -  Age ≥55 years&#xD;
&#xD;
          -  Office blood pressure ≥160/90mmHg in non-diabetics or ≥150/90mmHg in diabetics&#xD;
&#xD;
          -  Subjects must be on at least 3 anti-hypertensive drugs, including a diuretic agent&#xD;
&#xD;
          -  Sinus rhythm&#xD;
&#xD;
          -  Left ventricular hypertrophy defined on echo as:&#xD;
&#xD;
          -  Estimated LV mass &gt; 255 g or LVMI &gt;131 g/m2 for men&#xD;
&#xD;
          -  Estimated LV mass &gt;193 g or LVMI &gt;113 g/m2for women&#xD;
&#xD;
          -  Left atrial diameter ≥45mm on any echocardiographic window&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Estimated glomerular filtration rate (eGFR) &lt; 45ml/min/1.73m2&#xD;
&#xD;
          -  Renal artery anatomy unsuitable for RDN&#xD;
&#xD;
          -  Substantial stenotic valvular heart disease&#xD;
&#xD;
          -  Pregnancy or planned pregnancy&#xD;
&#xD;
          -  Thyrotoxicosis&#xD;
&#xD;
          -  Patients needing to undergo coronary artery bypass surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul A Brink, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Tygerberg Hospital and Stellenbosch University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Bohm, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Saarland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pace Clinic</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7505</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>November 9, 2013</study_first_submitted>
  <study_first_submitted_qc>November 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2013</study_first_posted>
  <last_update_submitted>September 21, 2020</last_update_submitted>
  <last_update_submitted_qc>September 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Pace Clinic</investigator_affiliation>
    <investigator_full_name>Marshall Jacobus Heradien</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>hypertension</keyword>
  <keyword>hypertensive heart disease</keyword>
  <keyword>atrial fibrillation</keyword>
  <keyword>autonomic imbalance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diuretics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

